Study of Inhaled TQC3721 for Moderate-to-Severe COPD
Part of Lungs & breathing clinical trials.
This trial tests an inhaled medication called TQC3721 for people with moderate-to-severe chronic obstructive pulmonary disease (COPD). It aims to see if the drug can improve lung function and symptoms. For some participants, the trial is available to those who have not been in a previous TQC3721 study.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have moderate-to-severe COPD diagnosed by your doctor.
- You are between 40 and 80 years old.
- You have a smoking history of at least 10 pack-years (e.g., 1 pack a day for 10 years) or have been exposed to biomass fuels.
- Your lung function after using a rescue inhaler shows FEV1/FVC less than 0.7 and FEV1 between 30% and 80% of predicted normal.
- You have been on stable COPD medications for at least 2 weeks before screening.
- You have not had a COPD flare-up needing steroids or a hospitalization in the last 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an inhaled medication called TQC3721 for people with moderate-to-severe COPD. The goal is to see if it can help improve breathing and reduce flare-ups.
This study tests a new inhaled powder medicine (TQC3927) against an existing combination inhaler for treating COPD, a lung disease that makes breathing difficult. The goal is to see if the new medicine works as well or better and is safe for people with COPD.
This study tests an oral tablet called RSS0343 for people with moderate to severe COPD. It aims to see if the tablet can improve lung function and reduce flare-ups when added to your current breathing treatments.
This trial tests a new drug, BBT002, first in healthy volunteers and then in people with chronic obstructive pulmonary disease (COPD) or chronic sinusitis with nasal polyps. It aims to see if the drug is safe and how it works in the body.
This trial tests an investigational drug called TQC2731 for people with severe asthma that is not well controlled despite high-dose inhaled steroids. The study aims to see if this treatment can reduce asthma attacks.
This trial tests an injectable drug called TQC2731 for people with chronic sinusitis and nasal polyps that haven't been controlled well enough by standard treatments like steroid sprays or surgery. The goal is to see if it helps reduce nasal congestion, improve sense of smell, and shrink polyps.
Hear when a new Chronic Obstructive Pulmonary Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.